Akebia Therapeutics, Inc.2024财年第二财季实现净利润-8.58百万美元，同比增加23.19%

自选股智能写手08-18

8月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2024财年第二财季净利润为-8.58百万美元，同比增加23.19%；其中营业收入为43.65百万美元，同比减少22.58%，每股基本收益为-0.04美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.54亿美元，其中短期债务7.19百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460736480?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-18 00:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460736480","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, Inc.2024财年第二财季实现净利润-8.58百万美元，同比增加23.19%","media":"自选股智能写手","content":"<div>\n<p>8月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2024财年第二财季净利润为-8.58百万美元，同比增加23.19%；其中营业收入为43.65百万美元，同比减少22.58%，每股基本收益为-0.04美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.54亿美元，其中短期债务7.19百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800063095a167ad&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, Inc.2024财年第二财季实现净利润-8.58百万美元，同比增加23.19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, Inc.2024财年第二财季实现净利润-8.58百万美元，同比增加23.19%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-18 00:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800063095a167ad&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2024财年第二财季净利润为-8.58百万美元，同比增加23.19%；其中营业收入为43.65百万美元，同比减少22.58%，每股基本收益为-0.04美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.54亿美元，其中短期债务7.19百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800063095a167ad&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800063095a167ad&s=b","article_id":"2460736480","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800063095a167ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460736480","pubTimestamp":1723910649,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月18日，Akebia Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-8.58百万美元，同比增加23.19%；其中营业收入为43.65百万美元，同比减少22.58%，每股基本收益为-0.04美元。从资产负债表来看，Akebia Therapeutics, Inc.总负债2.54亿美元，其中短期债务7.19百万美元，资产负债比为0.87，流动比率为1.05。机构评级：截至2024年8月18日，当前有3家机构对Akebia Therapeutics, Inc.目标价做出预测，其中目标均价为5.50美元，其中最低目标价为4.00美元，最高目标价为7.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Akebia Therapeutics, Inc. achieved net profit of-US $8.58 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 23.19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1,"LENZ":1},"content_text":"8月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2024财年第二财季净利润为-8.58百万美元，同比增加23.19%；其中营业收入为43.65百万美元，同比减少22.58%，每股基本收益为-0.04美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.54亿美元，其中短期债务7.19百万美元，资产负债比为0.87，流动比率为1.05。机构评级：截至2024年8月18日，当前有3家机构对Akebia Therapeutics, Inc.目标价做出预测，其中目标均价为5.50美元，其中最低目标价为4.00美元，最高目标价为7.50美元。公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。该公司的经营部门是开发和商业化用于肾脏疾病患者的新疗法。该公司目前的产品组合包括Auryxia(铁柠檬酸盐)，一种在美国批准并上市的药物，用于控制透析依赖性慢性肾病成人患者的血清磷水平和治疗缺铁性贫血，用于非透析依赖性慢性肾病成人患者，Vafseo (vadadustat)，一种口服缺氧诱导因子脯氨酰羟化酶抑制剂。HIF-PH抑制剂在日本被批准用于治疗成人慢性肾脏疾病引起的贫血，处于临床前开发阶段。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460736480"}